Dec 11, 2022

Hair Relaxer Manufacturers Oppose Centralization of Lawsuits Over Uterine Cancer, Ovarian Cancer, Fibroids

Posted by : Irvin Jackson

Defendants claim the cases involve too many different manufacturers, diseases and hair relaxer products for consolidation to be convenient or efficient.

  • Hair relaxer lawsuits have been filed in various different U.S. District Courts by women diagnosed with uterine cancer, ovarian cancer, fibroids and other injuries
  • Plaintiffs allege manufacturers knew about risks associated with toxic chemicals in hair relaxer
  • U.S. JPML has been asked to consolidate the claims as part of a hair relaxer MDL in the Northern District of Illinois
  • Manufacturers oppose the request and proposed the Southern District of New York as an alternative

Although a growing number of hair relaxer lawsuits are being filed throughout the federal court system by women diagnosed with uterine cancer, ovarian cancer and fibroids after use of popular products like Dark & Lovely, Just for Me, Optimum and others, manufacturers indicate they are opposed to centralizing the claims before one judge in the Northern District of Illinois.

L’Oreal, SoftSheen, Strength of Nature, House of Cheatham, Namasté Laboratories, and other manufacturers have marketed chemical hair relaxers as safe for decades, targeting Black women to promote straightening the natural curls in their hair. However, recent studies have found that hair relaxers or perms expose women to dangerous endocrine-disrupting chemicals, like phthalates, which increase the risk of cancer and other injuries.

Nearly a dozen lawsuits have been filed in various different U.S. District Courts, each raising similar allegations that the companies placed profits before the safety of consumers, by failing to disclose the potential cancer side effects of hair relaxers, and lawyers indicate that thousands of additional claims are likely to be filed in the coming months and years.

Hair Relaxer Lawsuits

Regular exposure to chemicals in hair relaxers may cause uterine cancer, breast cancer, and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.

Learn More About this Lawsuit See if you Qualify for a Settlement

Given common questions of fact and law raised in the complaints spread throughout the federal court system, a group of plaintiffs filed a motion to establish a hair relaxer MDL (multidistrict litigation) earlier this month, which would transfer the claims to one U.S, District Judge to preside over coordinated discovery and a series of early bellwether trials.

In complex product liability litigation, where large numbers of claims raise similar allegations against the manufacturers of similar products, it is common for the claims to be consolidated so that parties reduce duplicative discovery that would otherwise be repeated throughout large numbers of claims, avoid conflicting pretrial rulings and to serve the convenience of common parties and witnesses involved in the litigation.

Plaintiffs proposed that the hair relaxer litigation be centralized in the U.S. District Court for the Northern District of Illinois, before either Judge Mary Rowland or Judge Matthew Kennelly, who each already preside over at least one of the early lawsuits filed.

Cosmetics Industry Rejects Call for Hair Relaxer MDL

This week, responses were filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) by the cosmetic manufacturers L’Oreal (PDF), Dabur (PDF), House of Cheatham (PDF) and Strength of Nature (PDF), each opposing the centralization of the claims.

Although many of the products have been used by millions of women over more than four decades and may have caused tens of thousands of cases of uterine cancer, ovarian cancer, or uterine fibroids, the manufacturers argue that there are not currently enough cases filed to justify formal centralization, or that each of the claims involves individualized facts that would not make an MDL convenient or efficient.

“Movants allege that use of unspecified hair relaxers at unspecified times over the course of the last 50 years might increase the risk of a myriad of medical conditions ranging from uterine and breast cancer, to fibroids and endometriosis, to several other reproductive issues including, but not limited to, miscarriage, pre-term delivery, and irregular menstrual bleeding,” L’Oreal states in it’s brief. “These conditions are allegedly caused by at least 20 different products, manufactured by no fewer than five separate defendants.”€

The manufacturers do indicate that if the JPML does decide to consolidate the litigation, the hair relaxer MDL should be centralized in the Southern District of New York, which the companies presumably view as a more favorable venue.

It is expected that the U.S. JPML will consider oral arguments on the motion during an upcoming hearing session set for January 26, in Miami, Florida.

Hair Relaxer Cancer Risks

The litigation emerged after a number of studies published in recent years established a connection between use of hair relaxer and uterine cancer, raising concerns about the widespread use of the products by Black and other minority women throughout the U.S.

In October, researchers published findings in the Journal of the National Cancer Institute, which warned that ingredients used in the chemical hair relaxers may cause uterine cancer. Researchers found the rate of uterine cancer was nearly three times greater among women who frequently used hair relaxer chemicals, compared to women who never used the products.

A 2019 study published in the International Journal of Cancer (IJC) issued similar findings, indicating women who reported regularly using straighteners and permanent hair dyes were 9% more likely to develop breast cancer than non-users.

Over an eight-year period, researchers identified 2,794 cases of breast cancer after chemical hair straighteners use. The study revealed those who frequently used hair straightener products were at a significantly increased risk of breast cancer, finding women using hair straighteners at least every five to eight weeks, had a 30% increased risk of developing breast cancer.

Researchers warned that African American women who reported using permanent hair dyes regularly were associated with a 60% increase in breast cancer diagnosis, compared to an 8% increased risk for Caucasian women.

Uterine fibroids and endometriosis have been associated with phthalate metabolites used in hair relaxers.

As more women learn that their long-term use of hair relaxers may be the cause of uterine cancer, uterine fibroids, and other injuries linked to these endocrine-disrupting chemicals, the size and scope of the litigation are expected to increase dramatically.

Tags: Breast Cancer, Endocrine Disruptors, Endometriosis, Hair Relaxer, Hair Straighteners, L’Oreal, Phthalates, Uterine Cancer, Uterine Fibroids

The post Hair Relaxer Manufacturers Oppose Centralization of Lawsuits Over Uterine Cancer, Ovarian Cancer, Fibroids appeared first on

Be Sociable, Share!
author avatar
Irvin Jackson